An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer

Inclusion Criteria: 1. Adult males aged above 18 years old, no healthy volunteers included; 2. Prostate cancer confirmed by pathological findings; 3. High risk based on risk assessment, or laboratory tests suggestive of oligometastasis; 4. Agreement to undergo laparoscopic radical prostatectomy + pelvic lymphadenectomy; 5. ECOG score of 0 - 1 6. Agreement to undergo preoperative and postoperative endocrine therapy; 7. Voluntary signing of an ICF for the clinical trial Exclusion Criteria: 1. Any other tumor disease requiring treatment; 2. Any organ metastasis confirmed by imaging, such as liver and brain metastases, or the possibility of paralysis due to spinal cord metastasis; 3. A history of epilepsy or any condition that may lead to seizures; 4. Severe liver or kidney dysfunction, severe cardiovascular or cerebrovascular diseases, and systemic immune system diseases.